评估肾细胞癌全身治疗试验的入组标准
该研究分析了2012年6月30日至2022年6月30日间启动的肾细胞癌全身治疗I-III期试验的入组标准,共112项试验(占初始423项的26.5%)有足够信息。人类免疫缺陷病毒感染、乙型肝炎病毒/丙型肝炎病毒感染、脑转移及既往或并发恶性肿瘤的排除率分别为74.1%、53.6%、33.0%和8.0%。作者认为相当比例试验采用限制性入组标准,实施美国临床肿瘤学会-癌症研究之友(ASCO-FCR)建议可使数据更具包容性并与真实世界患者人群一致。
要点
- 112项肾细胞癌试验中,74.1%排除人类免疫缺陷病毒感染患者,53.6%排除乙型肝炎病毒/丙型肝炎病毒感染患者。
- 33.0%的试验排除脑转移患者,8.0%排除既往或并发恶性肿瘤患者。
- 作者认为实施ASCO-FCR建议可使试验数据更具包容性并贴合真实世界人群。
核心结论
- 相当比例的肾细胞癌试验采用限制性入组标准,排除了患有相当常见合并症的患者。
- 实施ASCO-FCR建议将确保所得数据更具包容性并与真实世界患者人群一致。
研究设计与样本
- 研究识别了2012年6月30日至2022年6月30日间启动的评估肾细胞癌患者全身治疗的I-III期试验。
- 初始识别423项肾细胞癌试验,其中112项(26.5%)具有足够的可获取信息。
- 将脑转移、既往或并发恶性肿瘤、乙型肝炎病毒或丙型肝炎病毒感染及人类免疫缺陷病毒感染的入组标准分为排除、条件性纳入和未报告三组。
- 采用描述性统计确定入组标准的频率,采用Fisher精确检验或卡方检验计算其与某些试验特征的关联。
主要发现
- 人类免疫缺陷病毒感染排除见于74.1%的试验,乙型肝炎病毒/丙型肝炎病毒感染排除见于53.6%的试验,脑转移排除见于33.0%的试验,既往或并发恶性肿瘤排除见于8.0%的试验。
- 在人类免疫缺陷病毒和乙型肝炎病毒/丙型肝炎病毒感染方面,患者大多被排除于评估免疫治疗的试验(分别为94.4%和77.8%)。
- 脑转移在评估靶向治疗(36.4%)、联合治疗(33.3%)和免疫治疗(22.2%)的试验中被排除。
- 既往或并发恶性肿瘤的排除较少报告,在靶向治疗、联合治疗和免疫治疗试验中分别占9.1%、8.3%和5.6%。
关键数值与推荐
- 人类免疫缺陷病毒感染排除率为74.1%。
- 乙型肝炎病毒/丙型肝炎病毒感染排除率为53.6%。
- 脑转移排除率为33.0%。
- 既往或并发恶性肿瘤排除率为8.0%。
- 在评估免疫治疗的试验中,人类免疫缺陷病毒感染和乙型肝炎病毒/丙型肝炎病毒感染的排除率分别为94.4%和77.8%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To characterise the restrictiveness of eligibility criteria in contemporary renal cell carcinoma (RCC) trials, using recommendations from the American Society of Clinical Oncology (ASCO)-Friends of Cancer Research (FCR) initiative. METHODS: vPhase I-III trials assessing systemic therapies in patients with RCC starting between 30 June 2012 and 30 June 2022 were identified. Eligibility criteria regarding brain metastases, prior or concurrent malignancies, hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, and human immunodeficiency virus (HIV) infection were identified and stratified into three groups: exclusion, conditional inclusion, and not reported. Descriptive statistics were used to determine the frequency of eligibility criteria. Fisher's exact test or chi-square test were used to calculate their associations with certain trial characteristics. RESULTS: A total of 423 RCC trials were initially identified of which 112 (26.5%) had sufficient accessible information. Exclusion of patients with HIV infection, HBV/HCV infection, brain metastases, and prior or concurrent malignancies were reported in 74.1%, 53.6%, 33.0%, and 8.0% of trials, respectively. In the context of HIV and HBV/HCV infection, patients were largely excluded from trials evaluating immunotherapy (94.4% and 77.8%, respectively). In addition, brain metastases were excluded in trials assessing targeted therapy (36.4%), combined therapy (33.3%), and immunotherapy (22.2%). Exclusion of patients with prior or concurrent malignancies was less frequently reported, accounting for 9.1%, 8.3%, and 5.6% targeted therapy, combined therapy and immunotherapy trials, respectively. CONCLUSION: A substantial proportion of RCC trials utilise restrictive eligibility criteria, excluding patients with fairly prevalent comorbidities. Implementing the ASCO-FCR recommendations will ensure resulting data are more inclusive and aligned with patient populations in the real-world.
引用
- Castro DV, Prajapati SR, Feng MI, et al. Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy. BJU Int. 2023. PMID: 37548533. doi:10.1111/bju.16148
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。